MedTrace Logo

A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

NCT04863365 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2021-06-18

No results posted yet for this study

Summary

This is a phase 3 study to confirm the efficacy in reduction of intraocular pressure and safety of PHP-201 ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

Placebo ophthalmic solution

A matching placebo ophthalmic solution, 3 drops daily, 28 days

DRUG

PHP-201 ophthalmic solution

PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days

Sponsors & Collaborators

  • pH Pharma

    lead INDUSTRY

Principal Investigators

  • Younyoung Hwang · pH Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2023-11-30
Completion
2023-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04863365 on ClinicalTrials.gov